Review




Structured Review

Eli Lilly bebtelovimab
Bebtelovimab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bebtelovimab/product/Eli Lilly
Average 90 stars, based on 1 article reviews
bebtelovimab - by Bioz Stars, 2026-02
90/100 stars

Images



Similar Products

93
MedChemExpress ly cov1404
Ly Cov1404, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly cov1404/product/MedChemExpress
Average 93 stars, based on 1 article reviews
ly cov1404 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Eli Lilly bebtelovimab
Bebtelovimab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bebtelovimab/product/Eli Lilly
Average 90 stars, based on 1 article reviews
bebtelovimab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
GenScript corporation bebtelovimab
(A, B) Neutralization profiles of GB-0669 and PRO-37587 as single agents or in combination (GB-0669 + PRO-37587), and isotype control mAb against pseudoviruses representative of SARS-CoV-2 D614G (ancestral strain), Omicron XBB.1.16.1, EG.5.1 and BA.2.86 variants. (A) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of four independent experiments, four technical replicates each). (B) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (A) are reported in the table. (C, D) Neutralization profiles of GB-0669 and PRO-37587 as single agents and combination (GB-0669 + PRO-37587), <t>bebtelovimab</t> and isotype control mAb against SARS-CoV-2 Eng20 (ancestral strain), Delta, Omicron BQ.1.1 and XBB.1.1 live viruses. (C) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of one experiment, three technical replicates). (D) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (C) are reported in the table. GB-0669, PRO-37587 and bebtelovimab tested as single agents were combined with isotype control mAb at the same concentrations to control for overall mass of GB-0669 and PRO-37587 tested in combination. The x-axis indicates the concentration of each individual antibody in the combinations.
Bebtelovimab, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bebtelovimab/product/GenScript corporation
Average 90 stars, based on 1 article reviews
bebtelovimab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Eli Lilly antibody treatments bebtelovimab
(A, B) Neutralization profiles of GB-0669 and PRO-37587 as single agents or in combination (GB-0669 + PRO-37587), and isotype control mAb against pseudoviruses representative of SARS-CoV-2 D614G (ancestral strain), Omicron XBB.1.16.1, EG.5.1 and BA.2.86 variants. (A) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of four independent experiments, four technical replicates each). (B) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (A) are reported in the table. (C, D) Neutralization profiles of GB-0669 and PRO-37587 as single agents and combination (GB-0669 + PRO-37587), <t>bebtelovimab</t> and isotype control mAb against SARS-CoV-2 Eng20 (ancestral strain), Delta, Omicron BQ.1.1 and XBB.1.1 live viruses. (C) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of one experiment, three technical replicates). (D) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (C) are reported in the table. GB-0669, PRO-37587 and bebtelovimab tested as single agents were combined with isotype control mAb at the same concentrations to control for overall mass of GB-0669 and PRO-37587 tested in combination. The x-axis indicates the concentration of each individual antibody in the combinations.
Antibody Treatments Bebtelovimab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody treatments bebtelovimab/product/Eli Lilly
Average 90 stars, based on 1 article reviews
antibody treatments bebtelovimab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
ProteoGenix bebtelovimab biosimilar–anti-sars-cov-2 spike protein mab–research grade
(A, B) Neutralization profiles of GB-0669 and PRO-37587 as single agents or in combination (GB-0669 + PRO-37587), and isotype control mAb against pseudoviruses representative of SARS-CoV-2 D614G (ancestral strain), Omicron XBB.1.16.1, EG.5.1 and BA.2.86 variants. (A) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of four independent experiments, four technical replicates each). (B) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (A) are reported in the table. (C, D) Neutralization profiles of GB-0669 and PRO-37587 as single agents and combination (GB-0669 + PRO-37587), <t>bebtelovimab</t> and isotype control mAb against SARS-CoV-2 Eng20 (ancestral strain), Delta, Omicron BQ.1.1 and XBB.1.1 live viruses. (C) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of one experiment, three technical replicates). (D) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (C) are reported in the table. GB-0669, PRO-37587 and bebtelovimab tested as single agents were combined with isotype control mAb at the same concentrations to control for overall mass of GB-0669 and PRO-37587 tested in combination. The x-axis indicates the concentration of each individual antibody in the combinations.
Bebtelovimab Biosimilar–Anti Sars Cov 2 Spike Protein Mab–Research Grade, supplied by ProteoGenix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bebtelovimab biosimilar–anti-sars-cov-2 spike protein mab–research grade/product/ProteoGenix
Average 90 stars, based on 1 article reviews
bebtelovimab biosimilar–anti-sars-cov-2 spike protein mab–research grade - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
AtaGenix Inc research grade bebtelovimab‐dvv00319
(A, B) Neutralization profiles of GB-0669 and PRO-37587 as single agents or in combination (GB-0669 + PRO-37587), and isotype control mAb against pseudoviruses representative of SARS-CoV-2 D614G (ancestral strain), Omicron XBB.1.16.1, EG.5.1 and BA.2.86 variants. (A) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of four independent experiments, four technical replicates each). (B) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (A) are reported in the table. (C, D) Neutralization profiles of GB-0669 and PRO-37587 as single agents and combination (GB-0669 + PRO-37587), <t>bebtelovimab</t> and isotype control mAb against SARS-CoV-2 Eng20 (ancestral strain), Delta, Omicron BQ.1.1 and XBB.1.1 live viruses. (C) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of one experiment, three technical replicates). (D) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (C) are reported in the table. GB-0669, PRO-37587 and bebtelovimab tested as single agents were combined with isotype control mAb at the same concentrations to control for overall mass of GB-0669 and PRO-37587 tested in combination. The x-axis indicates the concentration of each individual antibody in the combinations.
Research Grade Bebtelovimab‐Dvv00319, supplied by AtaGenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/research grade bebtelovimab‐dvv00319/product/AtaGenix Inc
Average 90 stars, based on 1 article reviews
research grade bebtelovimab‐dvv00319 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
ProteoGenix bebtelovimab
A HuMabs K501SP1 – K501SP7 and positive control <t>Bebtelovimab</t> (each represented by a different color as shown in the key) were tested for neutralization activity against ten SARS-CoV-2 isolates. B Calculated IC 50 ’s are plotted with each SARS-CoV-2 isolate represented by a different color, as shown in the key. Grey shading separates the different HuMabs and the dotted horizontal line shows the highest concentration of HuMab tested. Positive control Bebtelovimab was tested at no greater than 10 µg/mL. Throughout all graphs, data is represented as individual data points.
Bebtelovimab, supplied by ProteoGenix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bebtelovimab/product/ProteoGenix
Average 90 stars, based on 1 article reviews
bebtelovimab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A, B) Neutralization profiles of GB-0669 and PRO-37587 as single agents or in combination (GB-0669 + PRO-37587), and isotype control mAb against pseudoviruses representative of SARS-CoV-2 D614G (ancestral strain), Omicron XBB.1.16.1, EG.5.1 and BA.2.86 variants. (A) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of four independent experiments, four technical replicates each). (B) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (A) are reported in the table. (C, D) Neutralization profiles of GB-0669 and PRO-37587 as single agents and combination (GB-0669 + PRO-37587), bebtelovimab and isotype control mAb against SARS-CoV-2 Eng20 (ancestral strain), Delta, Omicron BQ.1.1 and XBB.1.1 live viruses. (C) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of one experiment, three technical replicates). (D) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (C) are reported in the table. GB-0669, PRO-37587 and bebtelovimab tested as single agents were combined with isotype control mAb at the same concentrations to control for overall mass of GB-0669 and PRO-37587 tested in combination. The x-axis indicates the concentration of each individual antibody in the combinations.

Journal: bioRxiv

Article Title: Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity

doi: 10.1101/2025.03.30.646023

Figure Lengend Snippet: (A, B) Neutralization profiles of GB-0669 and PRO-37587 as single agents or in combination (GB-0669 + PRO-37587), and isotype control mAb against pseudoviruses representative of SARS-CoV-2 D614G (ancestral strain), Omicron XBB.1.16.1, EG.5.1 and BA.2.86 variants. (A) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of four independent experiments, four technical replicates each). (B) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (A) are reported in the table. (C, D) Neutralization profiles of GB-0669 and PRO-37587 as single agents and combination (GB-0669 + PRO-37587), bebtelovimab and isotype control mAb against SARS-CoV-2 Eng20 (ancestral strain), Delta, Omicron BQ.1.1 and XBB.1.1 live viruses. (C) Results are reported as percentage (%) neutralization and shown as mean ± SD (representative of one experiment, three technical replicates). (D) EC50 and EC90 values (with 95% confidence intervals in parentheses) relative to the curves shown in (C) are reported in the table. GB-0669, PRO-37587 and bebtelovimab tested as single agents were combined with isotype control mAb at the same concentrations to control for overall mass of GB-0669 and PRO-37587 tested in combination. The x-axis indicates the concentration of each individual antibody in the combinations.

Article Snippet: CV3-25, , S2X259, the isotype control (palivizumab [anti-RSV F mAb] variable regions [ https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=7753 ] expressed as human IgG1 with LS mutation), bebtelovimab ( https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=12145 ), and sotrovimab VH/VL -huIgG1-LS (sotrovimab variable regions [ https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=11766 ] expressed as human IgG1 with LS mutation) were produced at GenScript.

Techniques: Neutralization, Control, Concentration Assay

(A-C) Golden Syrian hamsters (6 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), bebtelovimab, sotrovimab VH/VL - huIgG1-LS (sotrovimab variable regions expressed as human IgG1 with LS mutation), PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron BA.2 (2.8x10 3 TCID50/dose). Four days post-challenge the hamsters were euthanized, lungs were harvested, and the following parameters measured: (A) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 1,656 TCID50/g). (B, C) Copies of genomic RNA (B) and subgenomic RNA (C) per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). (D-F) hACE2 AC70 mice (10 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), pemivibart, PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron XBB.1.5. (D) Five mice per group were allowed to progress to study end date and percent survival for each group is reported up to day 14 post-challenge. (E, F) Five mice per group were euthanized on day 4 days post-challenge and lungs were harvested to quantify TCID50 and subgenomic RNA. (E) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 4,098 TCID50/g). (F) Copies of subgenomic RNA per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). Results in A-C, E and F are reported as individual data points, with lines representing median values. * and ** respectively indicate p ≤ 0.05 and p ≤ 0.01 when comparing experimental groups to isotype group.

Journal: bioRxiv

Article Title: Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity

doi: 10.1101/2025.03.30.646023

Figure Lengend Snippet: (A-C) Golden Syrian hamsters (6 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), bebtelovimab, sotrovimab VH/VL - huIgG1-LS (sotrovimab variable regions expressed as human IgG1 with LS mutation), PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron BA.2 (2.8x10 3 TCID50/dose). Four days post-challenge the hamsters were euthanized, lungs were harvested, and the following parameters measured: (A) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 1,656 TCID50/g). (B, C) Copies of genomic RNA (B) and subgenomic RNA (C) per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). (D-F) hACE2 AC70 mice (10 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), pemivibart, PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron XBB.1.5. (D) Five mice per group were allowed to progress to study end date and percent survival for each group is reported up to day 14 post-challenge. (E, F) Five mice per group were euthanized on day 4 days post-challenge and lungs were harvested to quantify TCID50 and subgenomic RNA. (E) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 4,098 TCID50/g). (F) Copies of subgenomic RNA per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). Results in A-C, E and F are reported as individual data points, with lines representing median values. * and ** respectively indicate p ≤ 0.05 and p ≤ 0.01 when comparing experimental groups to isotype group.

Article Snippet: CV3-25, , S2X259, the isotype control (palivizumab [anti-RSV F mAb] variable regions [ https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=7753 ] expressed as human IgG1 with LS mutation), bebtelovimab ( https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=12145 ), and sotrovimab VH/VL -huIgG1-LS (sotrovimab variable regions [ https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=11766 ] expressed as human IgG1 with LS mutation) were produced at GenScript.

Techniques: Control, Mutagenesis

A HuMabs K501SP1 – K501SP7 and positive control Bebtelovimab (each represented by a different color as shown in the key) were tested for neutralization activity against ten SARS-CoV-2 isolates. B Calculated IC 50 ’s are plotted with each SARS-CoV-2 isolate represented by a different color, as shown in the key. Grey shading separates the different HuMabs and the dotted horizontal line shows the highest concentration of HuMab tested. Positive control Bebtelovimab was tested at no greater than 10 µg/mL. Throughout all graphs, data is represented as individual data points.

Journal: Communications Biology

Article Title: Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages

doi: 10.1038/s42003-024-06951-7

Figure Lengend Snippet: A HuMabs K501SP1 – K501SP7 and positive control Bebtelovimab (each represented by a different color as shown in the key) were tested for neutralization activity against ten SARS-CoV-2 isolates. B Calculated IC 50 ’s are plotted with each SARS-CoV-2 isolate represented by a different color, as shown in the key. Grey shading separates the different HuMabs and the dotted horizontal line shows the highest concentration of HuMab tested. Positive control Bebtelovimab was tested at no greater than 10 µg/mL. Throughout all graphs, data is represented as individual data points.

Article Snippet: Bebtelovimab (ProteoGenix, CAS 2578319-11-4, PX-TA1750, 1 mg/mL) used at a final concentration of 10 µg/mL and plasma from a Corminarty® vaccinated, convalescent individual was used as a positive control for each isolate .

Techniques: Positive Control, Neutralization, Activity Assay, Concentration Assay